H. Tilly

H. Tilly, P. Chamouni, N. Contentin, 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with

T. Molina, B. Coiffier, H. Tilly, 2009 .

CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

T. Molina, H. Tilly, B. Quesnel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

T. Molina, B. Coiffier, H. Tilly, 2005, The New England journal of medicine.

Assessing the Cox model assumption as a statistical tool for classifying lymphomas.

B. Coiffier, H. Dombret, F. Morschhauser, 2001, The hematology journal : the official journal of the European Haematology Association.

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

P. Gaulard, G. Salles, B. Coiffier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, P. Biron, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.

Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia

H. Tilly, C. Bastard, C. Fruchart, 1996, American journal of hematology.

Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

P. Gaulard, H. Tilly, E. Labouyrie, 2003 .

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

P. Gaulard, H. Tilly, E. Labouyrie, 2003, Blood.

Change in energy and protein status during chemotherapy in patients with acute leukemia

H. Tilly, É. Lerebours, A. Rimbert, 1988, Cancer.

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

R. Houot, B. Coiffier, R. Bouabdallah, 2016, British journal of haematology.

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia

H. Tilly, N. Ifrah, H. Esperou, 1997 .

Human herpesvirus-6 acute limbic encephalitis after unrelated umbilical cord blood transplantation successfully treated with ganciclovir

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Bone Marrow Transplantation.

P. Gaffney, J. Cerhan, T. Molina, 2017, Lupus Science & Medicine.

Cyclosporin for treatment of life‐threatening alloimmunization

H. Tilly, H. Piguet, A. Lallemand, 1990, American journal of hematology.

Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study

T. Molina, F. Jardin, G. Salles, 2008 .

Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas

F. Jardin, J. Picquenot, H. Tilly, 2008, Haematologica.

Spontaneous remission in three cases of AML M5 with NPM1 mutation

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Clinical case reports.

In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas

T. Molina, F. Berger, F. Carrat, 2016, PloS one.

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

T. Molina, F. Berger, F. Carrat, 2015, American journal of hematology.

Circulating tumor DNA: an important tool in precision medicine for lymphoma

F. Jardin, H. Tilly, É. Bohers, 2018 .

HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors.

H. Tilly, P. Morlat, M. Raphael, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma

F. Jardin, J. Picquenot, S. Mareschal, 2017, Oncotarget.

Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology

F. Jardin, P. Gaulard, J. Picquenot, 2006, Oncogene.

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.

W. Klapper, E. Hoster, G. Salles, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma

R. Houot, F. Jardin, G. Salles, 2017, The New England journal of medicine.

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

P. Gaulard, G. Salles, A. Rahmouni, 2013, Haematologica.

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.

G. Salles, B. Coiffier, H. Tilly, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, N. Brousse, É. Lepage, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pyothorax-Associated Lymphoma: A Peculiar Clinicopathologic Entity Derived From B Cells at Late Stage of Differentiation and With Occasional Aberrant Dual B- and T-Cell Phenotype

C. Copie-Bergman, F. Jardin, P. Gaulard, 2002, The American journal of surgical pathology.

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Catherine Thieblemont, Nicolas Mounier, Richard Delarue, 2013, The Lancet. Oncology.

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.

R. Bouabdallah, H. Tilly, N. Brousse, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

S. Montoto, H. Tilly, C. Crawley, 2013, Bone Marrow Transplantation.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

A. Hagenbeek, G. Salles, F. d'Amore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

F. Jardin, P. Gaulard, H. Tilly, 2021, Leukemia & lymphoma.

Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study

F. Jardin, H. Lanic, S. Leprêtre, 2021, European Journal of Haematology.

Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma

H. Tilly, V. Camus, 2017, Expert review of hematology.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

J. Jais, P. Feugier, H. Tilly, 2017, Blood.

The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential

F. Jardin, H. Tilly, V. Camus, 2017, Expert review of molecular diagnostics.

Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2016, Leukemia & lymphoma.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

J. Cerhan, G. Salles, T. Habermann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.

T. Molina, F. Jardin, G. Salles, 2015, The Journal of molecular diagnostics : JMD.

Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

T. Molina, B. Coiffier, J. Jais, 2014 .

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

G. Salles, L. Xerri, P. Feugier, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

Annibale Versari, Michel Meignan, Fabien Ricard, 2014, The Lancet. Haematology.

The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age

F. Jardin, H. Lanic, S. Mareschal, 2011, Haematologica.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab

T. Molina, P. Gaulard, G. Salles, 2008, Leukemia.

Novel Ig V gene features of t(14;18) and t(3;14) de novo diffuse large B-cell lymphoma displaying germinal center-B cell like and non-germinal center-B cell like markers

F. Jardin, S. Leprêtre, H. Tilly, 2006, Leukemia.

[Clinical application of gene-expression profiling in lymphome].

F. Jardin, H. Tilly, 2004, Medecine sciences : M/S.

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2011, Clinical lymphoma, myeloma & leukemia.

High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis

K. Tarte, F. Jardin, H. Tilly, 2012, Leukemia.

Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas

F. Jardin, A. Stamatoullas, H. Lanic, 2021, Haematologica.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

G. Salles, A. López-Guillermo, L. Xerri, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts

J. Cerhan, K. Tarte, F. Jardin, 2018, The Lancet. Oncology.

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

G. Salles, M. Federico, H. Tilly, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma

S. Mareschal, H. Tilly, C. Haioun, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

T. Molina, F. Jardin, G. Salles, 2013, Leukemia.

Rituximab maintenance therapy for follicular lymphoma – Authors' reply

G. Salles, A. López-Guillermo, H. Tilly, 2011, The Lancet.

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non‐Hodgkin's lymphoma

A. Stamatoullas, H. Tilly, C. Fruchart, 1996, Cancer.

Cyberlindnera jadinii (teleomorph Candida utilis) candidaemia in a patient with aplastic anaemia: a case report

F. Jardin, A. Stamatoullas, H. Lanic, 2018, JMM case reports.

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

C. Copie-Bergman, T. Molina, F. Jardin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

H. Tilly, B. Siegel, C. Haioun, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

H. Tilly, É. Lepage, C. Haioun, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).

H. Tilly, C. Crawley, P. Biron, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic

M. Kersten, C. Buske, M. Federico, 2021, HemaSphere.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

J. Raemaekers, M. Pfreundschuh, H. Tilly, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

F. Jardin, H. Tilly, S. Chevret, 2014, Genes, chromosomes & cancer.

Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1.

H. Tilly, D. Blaise, D. Maraninchi, 1991, Bone Marrow Transplantation.

The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.

S. Montoto, R. Bouabdallah, M. Pfreundschuh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

T. Molina, B. Coiffier, H. Tilly, 2010, Leukemia & lymphoma.

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?

F. Jardin, J. Picquenot, H. Lanic, 2015, Oncotarget.

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

A. Stamatoullas, H. Tilly, H. Kluin-Nelemans, 2019, Health and Quality of Life Outcomes.

Human monocytes synthesize hyaluronidase

H. Tilly, B. Delpech, J. Vannier, 2002, British journal of haematology.

Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value.

H. Tilly, M. Lefranc, S. Daliphard, 1994, Leukemia.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

M. Kersten, M. Millenson, H. Tilly, 2018, The Lancet. Haematology.

Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?

F. Jardin, H. Tilly, A. Hitzel, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.

R. Houot, E. Macintyre, H. Tilly, 2020, The Lancet. Haematology.

RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

G. Salles, O. Casasnovas, H. Tilly, 2008 .

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

C. Copie-Bergman, T. Molina, F. Jardin, 2016, Clinical Cancer Research.

Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.

T. Molina, F. Jardin, G. Salles, 2017, The Journal of molecular diagnostics : JMD.

Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib.

F. Jardin, H. Tilly, A. Laquérriere, 2005, The Lancet Oncology.

Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma

F. Jardin, H. Tilly, V. Camus, 2019, British Journal of Ophthalmology.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia & lymphoma.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. Ziepert, N. Schmitz, C. Flowers, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

R. Greil, J. Burke, G. Salles, 2021, The New England journal of medicine.

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

L. Vercellino, P. Gaulard, G. Salles, 2020, Blood.

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

T. Molina, O. Casasnovas, P. Feugier, 2022, Blood advances.

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

H. Tilly, P. Chevallier, D. Blaise, 2016, Bone Marrow Transplantation.

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

H. Tilly, M. Henry-Amar, L. Degos, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

G. Salles, O. Casasnovas, H. Tilly, 2014 .

Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia

F. Jardin, J. Picquenot, F. Clatot, 2016, Leukemia.

Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes

H. Tilly, X. Troussard, O. Hermine, 2000, Leukemia.

Brain Perfusion in Adult Patients with Acute Myeloblastic Leukemia before and after Cytosine Arabinoside

O. Martinaud, D. Hannequin, R. Modzelewski, 2011, Molecular Imaging and Biology.

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

J. Blay, S. Leprêtre, H. Tilly, 2011, Hematological oncology.

Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?

F. Jardin, H. Tilly, 2022, The Lancet. Healthy longevity.

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

P. Gaulard, J. Zucman‐Rossi, E. Solary, 2013, Haematologica.

FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts

J. Cerhan, T. Molina, G. Salles, 2017, Hematological oncology.

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

G. Salles, L. Sehn, J. Friedberg, 2019, Journal of Clinical Oncology.

Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

R. Advani, A. Hagenbeek, G. Salles, 2014 .

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

B. Coiffier, H. Tilly, T. Robak, 2005 .

International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.

M. Ziepert, N. Schmitz, G. Salles, 2020, Blood.

Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.

M. Dyer, A. Hagemeijer, H. Tilly, 1996, Leukemia.

Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay

C. Copie-Bergman, F. Jardin, P. Gaulard, 2019, Haematologica.

90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, R. Bouabdallah, H. Tilly, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

R. Greil, P. Gaulard, B. Coiffier, 2019, British journal of haematology.

Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

M. Pfreundschuh, H. Tilly, D. Blaise, 2008, Haematologica.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J. Cerhan, T. Molina, G. Salles, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

P. Gaulard, G. Salles, M. Copin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

F. Jardin, A. Stamatoullas, S. Leprêtre, 2015, Anticancer research.

Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma

F. Jardin, A. Stamatoullas, H. Lanic, 2022, European journal of haematology.

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation.

H. Tilly, N. Ifrah, H. Esperou, 1997, British journal of haematology.

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age

A. Stamatoullas, H. Tilly, C. Fruchart, 1997, Bone Marrow Transplantation.

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

H. Tilly, M. Labopin, A. Nagler, 2020, Bone Marrow Transplantation.

Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Mycopathologia.

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2020, Blood Cancer Journal.

R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B

C. Copie-Bergman, T. Molina, F. Jardin, 2011 .

Recurrent disruption of the Imu splice donor site in t(14;18) positive lymphomas: a potential molecular basis for aberrant downstream class switch recombination.

F. Jardin, J. Picquenot, H. Tilly, 2007, Genes, chromosomes & cancer.

Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

B. Coiffier, P. Feugier, H. Tilly, 2011, Leukemia & lymphoma.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, J. Diebold, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.

F. Jardin, G. Salles, P. Feugier, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.

G. Salles, A. López-Guillermo, R. Bouabdallah, 2018 .

Bendamustine and rituximab in elderly patients with low‐tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study

R. Bouabdallah, L. Xerri, P. Feugier, 2018, British journal of haematology.

ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients

A. Rosenwald, D. Weisenburger, J. Armitage, 2019, Haematologica.

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

R. Bouabdallah, H. Tilly, C. Gisselbrecht, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

P. Feugier, H. Tilly, C. Haioun, 2021, Cancers.

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma

Philippe Bertrand, Pierre Vera, Sylvain Mareschal, 2012, Leukemia & lymphoma.

Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study

B. Coiffier, H. Tilly, N. Mounier, 2015, Leukemia & lymphoma.

Invasive Geotrichum clavatum Fungal Infection in an Acute Myeloid Leukaemia Patient: A Case Report and Review

F. Jardin, A. Stamatoullas, H. Lanic, 2014, Mycopathologia.

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

B. Coiffier, R. Bouabdallah, H. Holte, 2013 .

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Pfreundschuh, H. Tilly, M. André, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Miescher cheilitis and myelomonocytic leukemia: a fortuitous association or a rare paraneoplastic syndrome?

F. Jardin, A. Stamatoullas, H. Tilly, 2010, Leukemia & lymphoma.

Treatment of follicular lymphoma: current status

A. Zelenetz, H. Tilly, 2008, Leukemia and Lymphoma.

Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

F. Jardin, A. Stamatoullas, H. Tilly, 2020, Clinical case reports.

Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements

F. Jardin, A. Stamatoullas, S. Leprêtre, 2002, Leukemia.

Intense paraneoplastic neutrophilic leukemoid reaction related to a G‐CSF‐Secreting lung sarcoma

F. Jardin, L. Thiberville, H. Tilly, 2005, American journal of hematology.

Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

H. Tilly, V. Camus, 2020, Future oncology.

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2021, Cancer.

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2019, Cancer.

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)

G. Salles, O. Casasnovas, H. Tilly, 2015, Cancer Chemotherapy and Pharmacology.

Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

F. Jardin, B. Coiffier, H. Tilly, 2014 .

Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.

G. Salles, L. Guerra, M. Federico, 2014 .

Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era

F. Jardin, G. Salles, H. Tilly, 2015, Leukemia & lymphoma.

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, European journal of haematology.

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, Blood.

INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

G. Salles, J. Radford, H. Tilly, 2019, Hematological Oncology.

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

G. Salles, O. Casasnovas, P. Feugier, 2016 .

Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma

F. Jardin, J. Picquenot, H. Tilly, 2013, Leukemia & lymphoma.

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

W. Klapper, E. Hoster, W. Hiddemann, 2017 .

Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas

J. Picquenot, H. Tilly, C. Bastard, 2008, Leukemia.

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

B. Coiffier, R. Bouabdallah, O. Casasnovas, 2013, European journal of cancer.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

C. Copie-Bergman, F. Jardin, A. Rahmouni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study

P. Gaulard, G. Salles, J. Jais, 2023, British journal of haematology.

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Pierre Vera, Emmanuel Itti, Romain Modzelewski, 2017, The Journal of Nuclear Medicine.

Lymphomes non hodgkiniens

H. Tilly, F. Jardin, 2006 .

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Blood Cancer Journal.

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

G. Salles, L. Sehn, A. López-Guillermo, 2019, Blood.

Double Hit Lymphoma Diagnosis and Treatment in Europe—A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG)

M. Kersten, E. Kimby, M. Federico, 2020, HemaSphere.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

F. Jardin, B. Coiffier, H. Tilly, 2017, The Lancet. Haematology.

Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.

F. Jardin, H. Tilly, A. Italiano, 2005, Haematologica.

Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

B. Coiffier, P. Feugier, H. Tilly, 2005 .

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

F. Jardin, J. Picquenot, S. Mareschal, 2015, Haematologica.

Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study.

T. Molina, P. Gaulard, G. Salles, 2007 .

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly

R. Bouabdallah, A. Stamatoullas, H. Lanic, 2015, British journal of haematology.

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.

P. Gaulard, H. Tilly, C. Haioun, 2017, European journal of cancer.

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment

P. Cony-Makhoul, H. Tilly, L. Chartier, 2023, British journal of haematology.

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012 .

Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update

H. Tilly, X. Troussard, N. Ifrah, 2004, Leukemia.

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell Lymphoma: Is There a Superior Method?

H. Tilly, P. Vera, S. Becker, 2021, Metabolites.

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2016, Haematologica.

[Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration].

H. Tilly, N. Contentin, S. Dominique, 2003, Revue des maladies respiratoires.

A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.

H. Tilly, J. Tanzer, F. Bauters, 1991, European journal of cancer.

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

P. Riedell, H. Tilly, Jitendra Kanodia, 2022, Blood.

Accurate Classification Of GCB/ABC and MYC/BCL2 Diffuse Large B-Cell Lymphoma With a 14 Genes Expression Signature and a Simple and Robust RT-MLPA Assay

F. Jardin, J. Jais, J. Picquenot, 2013 .

Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Leukemia & lymphoma.

Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).

G. Salles, H. Tilly, N. Milpied, 2009 .

F. Jardin, J. Picquenot, H. Tilly, 2009, Leukemia.

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm

F. Jardin, A. Stamatoullas, J. Picquenot, 2011, British journal of haematology.

Effect of chemotherapy on resting energy expenditure in patients with non‐Hodgkin's lymphoma results of a sequential study

H. Tilly, É. Lerebours, A. Rimbert, 1990, Cancer.

[Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature].

F. Jardin, A. Stamatoullas, H. Tilly, 1999, La Revue de medecine interne.

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

R. Advani, A. Hagenbeek, G. Salles, 2014 .

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

L. Sehn, Junjie Cao, H. Tilly, 2023, Blood.

Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL)

B. Coiffier, J. Radford, H. Tilly, 2007 .

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2020, Blood Cancer Journal.

A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.

P. Gaulard, B. Coiffier, F. Morschhauser, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL)

H. Tilly, C. Haioun, A. Biggi, 2012 .

Voltage-Gated Potassium Channel Antibody Paraneoplastic Limbic Encephalitis Associated with Acute Myeloid Leukemia

F. Jardin, S. Leprêtre, H. Tilly, 2013, Case Reports in Oncology.

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

R. Advani, R. Bouabdallah, H. Tilly, 2015, Leukemia & lymphoma.

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

G. Salles, J. Radford, H. Tilly, 2019, Blood.

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

G. Salles, R. Morin, J. Radford, 2017 .

A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease

G. Salles, H. Tilly, N. Milpied, 2008 .

Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study

P. Gaulard, B. Coiffier, H. Tilly, 1993 .

Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).

M. Ziepert, G. Salles, C. Flowers, 2019, Journal of Clinical Oncology.

Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

F. Jardin, H. Tilly, C. Haioun, 2009 .

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

J. Cerhan, T. Molina, G. Salles, 2017 .

A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma

R. Houot, G. Salles, H. Tilly, 2014 .

Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.

T. Molina, G. Salles, R. Bouabdallah, 2013, Clinical advances in hematology & oncology : H&O.

[Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases].

F. Sigaux, H. Tilly, P. Colombat, 1985, Nouvelle revue francaise d'hematologie.

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05

B. Coiffier, R. Bouabdallah, O. Casasnovas, 2010 .

REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM

R. Houot, G. Salles, H. Tilly, 2019, Hematological Oncology.

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

R. Houot, G. Salles, H. Tilly, 2019, HemaSphere.

Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma

F. Jardin, J. Picquenot, S. Mareschal, 2015 .

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)

G. Salles, R. Bouabdallah, P. Feugier, 2010 .

Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.

F. d'Amore, J. Radford, H. Tilly, 2007 .

Severe Acquired Neutropenia Associated with Anti-Proteinase 3 Antibodies

F. Jardin, H. Tilly, F. Jouen, 2011, Acta Haematologica.

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study

G. Salles, M. Fulham, H. Tilly, 2010 .

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay

Philippe Ruminy, David Gentien, Randy D Gascoyne, 2017, Haematologica.

Autologous blood stem cell collection after chemotherapy for malignancies : data for an optimal yield

H. Tilly, P. Vannier, D. Bastit, 1990 .

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

G. Salles, M. Federico, H. Tilly, 2016 .

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA

R. Houot, G. Salles, R. Bouabdallah, 2017 .

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

A. Rosenwald, M. Ziepert, T. Molina, 2023, Blood advances.

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Blood Cancer Journal.

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Pfreundschuh, H. Tilly, M. André, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

J. Gribben, G. Salles, J. Radford, 2018, Blood.

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study

F. Jardin, H. Lanic, S. Mareschal, 2011, Haematologica.

Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS

G. Salles, L. Xerri, P. Feugier, 2012 .

Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

C. Copie-Bergman, T. Molina, F. Jardin, 2015 .

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

C. Copie-Bergman, F. Jardin, A. Rahmouni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.

G. Salles, L. Sehn, A. Zelenetz, 2016 .

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).

H. Tilly, C. Crawley, P. Biron, 2012 .

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, New England Journal of Medicine.

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

H. Tilly, M. Trněný, R. Delarue, 2023, HemaSphere.

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

G. Salles, L. Sehn, A. Zelenetz, 2016 .

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

J. Cerhan, T. Molina, G. Salles, 2013 .

Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma.

F. Jardin, R. Modzelewski, H. Tilly, 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

J. Leonard, B. Cheson, H. Holte, 2006 .

Rearrangements in Non-Hodgkin ' s Lymphoma : Correlation With Histology , Immunophenotype , Karyotype , and Clinical Outcome in 217 Patients

H. Tilly, C. Bastard, F. Pezzella, 2000 .

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia and Lymphoma.

Gene Expression Profiling of Highly Purified Malignant and Non-Malignant Cells: Characterization of the Tumor-Microenvironment Cellular Synapse in De Novo Follicular Lymphoma (FL).

J. D. Vos, K. Tarte, J. Picquenot, 2007 .

Follicular lymphoma international prognostic index.

A. López-Guillermo, H. Tilly, P. Zinzani, 2004, Blood.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

B. Coiffier, F. d'Amore, M. Federico, 2014, Cancer treatment reviews.